TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02234895

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral wedge
Description: This will be a randomized cross-over study where all participants will receive both orthoses over a six month period. Each intervention will last two months, separated by a two month washout period of no orthotics wear, and will be preceded and followed by a laboratory-based gait and pain assessment. Two months has been chosen as the ideal time frame to ensure maximum participant adherence, to observe clinically meaningful changes in symptoms, and to minimize degradation of the insoles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral wedge plus medial arch support
Description: This will be a randomized cross-over study where all participants will receive both orthoses over a six month period. Each intervention will last two months, separated by a two month washout period of no orthotics wear, and will be preceded and followed by a laboratory-based gait and pain assessment. Two months has been chosen as the ideal time frame to ensure maximum participant adherence, to observe clinically meaningful changes in symptoms, and to minimize degradation of the insoles.
Study: NCT00947882

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mannitol 50 mg/mL solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix 10 mg
Description: 10 mg degarelix, 40 mg/mL solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix 20 mg
Description: 20 mg degarelix, 40 mg/mL solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix 30 mg
Description: 30 mg degarelix, 40 mg/mL solution
Study: NCT01947140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate
Description: Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 10 mg/m2 to 25 mg/m2~Phase II - 25 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate
Description: Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 10 mg/m2 to 25 mg/m2~Phase II - 25 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate
Description: Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 10 mg/m2 to 25 mg/m2~Phase II - 25 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 12 mg/m2 to 14 mg/m2.~Phase II - 12 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 12 mg/m2 to 14 mg/m2.~Phase II - 12 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 12 mg/m2 to 14 mg/m2.~Phase II - 12 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle.
Study: NCT01385527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Internet survey
Description: Parents will complete a weekly online survey about medication use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Triamcinolone
Description: Topical triamcinolone to all affected areas once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Triamcinolone
Description: Topical triamcinolone to all affected areas once daily
Study: NCT00634907

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic-based warfarin dosing
Description: Prior to elective joint replacement surgery a blood sample is collected for genetic information(genotyping)which was used for calculating warfarin doses for patients randomized to the cytochrome arm. Outcomes in terms of efficacy, safety, and management of warfarin were compared between this group and the group in which warfarin doses are determined per usual care.~NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm as noted above.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care warfarin dosing
Description: For patients in arm 2, the control group, warfarin dosing is per usual care. Outcomes in terms of safety, efficacy, and warfarin management was compared to that of patients in the other arm, who receive warfarin dosing based on genotyping.~NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm as noted above.
Study: NCT01820039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FertiScreen
Description: FertiScreen is an online application to assess whether referral is necessary or expectant management is indicated.
Study: NCT02192736

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Trophic factors from umbilical cord mesenchymal stem cells
Study: NCT04834037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: The provision of information and supportive nursing care is recommended to alleviate anxiety, stress and agitation in COPD patients treated with NIV.
Study: NCT01166542

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: REOLYSIN
Description: 3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: 5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: 5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03444038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: vesicular monoamine transporter 2 (VMAT2) inhibitor
Study: NCT00795665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab (10 mg/kg) will be given intravenously every other week starting one week before the first dose of BCNU. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: BCNU (200 mg/m2), will be given over 4 hours as a continuous intravenous infusion every 8 weeks. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
Study: NCT02679677

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Whole Body Vibration
Description: The principle of the Galileo vibration platform is a side alternating motion similar to a childrens seesaw. Both the amplitude of movement and the frequency of movement may be altered. Frequency may be controlled on the device and settings range from 5Hz to 30Hz. Amplitude of movement is set by spreading one's legs further apart from the midline. Control arm participants remain fixed at 5Hz through the 6 week training period, while intervention arm participants steadily increase their frequency to a maximum of 28Hz.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration
Description: The principle of the Galileo vibration platform is a side alternating motion similar to a childrens seesaw. Both the amplitude of movement and the frequency of movement may be altered. Frequency may be controlled on the device and settings range from 5Hz to 30Hz. Amplitude of movement is set by spreading one's legs further apart from the midline. Control arm participants remain fixed at 5Hz through the 6 week training period, while intervention arm participants steadily increase their frequency to a maximum of 28Hz.
Study: NCT04297280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: a PD-1 immune check inhibitor

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE is performed by using drug eluting beads, or using embolic agent combined with Lipiodol-pirarubicin emulsion per Investigator decision
Study: NCT03914313

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Treatment plus VR
Description: The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a rehabilitation training with the Lokomat-Pro, in which the exoskeleton device is equipped with a screen with virtual reality. The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). The Lokomat-Pro will be used to improve gait, whereas motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Treatment plus VR
Description: The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a rehabilitation training with the Lokomat-Pro, in which the exoskeleton device is equipped with a screen with virtual reality. The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). The Lokomat-Pro will be used to improve gait, whereas motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Treatment plus VR
Description: The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a rehabilitation training with the Lokomat-Pro, in which the exoskeleton device is equipped with a screen with virtual reality. The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). The Lokomat-Pro will be used to improve gait, whereas motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatment.
Study: NCT00269048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-480848
Description: SB-480848

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00723554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost PD-6
Description: Period 1 (PD-6): study period defined as the 14 days prior to the first dose of study iloprost inhalation with PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-6 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost PD-15
Description: Period 2 (PD-15): study period between the administration of the first dose with PD-15 on Day 1 until Day 28 inclusive.~Period 3 (PD-15): study period from Day 29 until discontinuation of the PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-15 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day
Study: NCT00756288

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topical retinoid and blue-light therapy with photosensitizing agent
Description: Topical Retinoid - Apply to AKs for 4 weeks Photo-therapy with photosensitizing agent- Apply to AKs at week 4

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic Therapy (PDT)
Description: Photo-therapy with sensitizing agent - apply to AKs at week 4
Study: NCT02016300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unloader Bracing
Description: The bracing arm patients will be randomly selected and will wear an unloader brace post-operatively during the study period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Bracing
Description: Microfracture performed with no post-operative unloader bracing
Study: NCT00854321

Intervention type: DRUG
Intervention: rituximab
Description: rituximab two 1000 mg intravenous infusions separated by two weeks

Intervention type: DRUG
Intervention: rituximab, observational study amon patients with active RA
Description: two 1000 mg intravenous infusions separated by 2 weeks
Study: NCT01625637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AAT-experiment
Description: This AAT condition trains kids to avoid cigarettes

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: AAT-placebo
Description: This AAT condition is a no contingency continued assessment version (50% approach-cigarettes, 50% avoid cigarettes).
Study: NCT02463149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Chef Academy
Description: Nutrition and culinary curriculum delivered in the classroom
Study: NCT00878995

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Testosterone
Description: Placebo (Saline) Testosterone given IM once per week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Enanthate 100 MG/ML
Description: Testosterone Enanthate 100mg/ml given once per week IM.
Study: NCT02583503

Intervention type: RADIATION
Intervention: Hindfoot alignment view x ray
Description: Diagnostic x rays used to measure leg alignment.
Study: NCT01031537

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FSME-IMMUN 0.5ml Baxter
Description: Vaccine
Study: NCT02187978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early total enteral feeding (ETEF)
Description: In ETEF Group total required volume of fluid will be administered as oral feeds and no intravenous fluid will be given. Feeds will be started at 80 mL/kg and increased till 150ml/kg is attained.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional enteral feeding (CEF)
Description: CEF Group will receive some feed and some Intravenous fluids. Feeds will be slowly increased from 20 mL/kg on day 1 till full feeds 150ml/kg is attained on day 6 of life.
Study: NCT02642666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Children's Yoga
Description: Trained children's yoga instructors will guide the children through 30 minute yoga classes (in-person and on the yoga video), using a manualized curriculum from If I Was a Bird Yoga ™ with child centered themes. Each class will have a similar structure, set of poses, and breathing exercises, but the theme of the class will change every two weeks. The themes for the classes are ocean yoga adventure, jungle yoga adventure and outer space yoga adventure. The study participants will spend two weeks practicing the same theme at home and at school before moving on to the next theme.
Study: NCT01644890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK105
Description: IV, Weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV, Weekly
Study: NCT01406678

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RIPC
Description: 3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion
Study: NCT02967224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine (U300)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine (U100)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT01508806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose of 0.75 mg, administered as a subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose of 0.75 mg, administered as a subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose of 0.75 mg, administered as a subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose of 0.75 mg, administered as a subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose of 0.75 mg, administered as a subcutaneous injection
Study: NCT03327103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAMPION
Description: An interactive mHealth decision aid that includes immediate and over time quality of life (QL) graphical summaries for advanced prostate cancer patients to enhance informed, shared decision making and will also be used to assess the CPNs' role in the decision-making process.
Study: NCT02784067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucraid
Description: Study drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sucraid placebo
Study: NCT02211170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 796 BS, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 796 BS, high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide
Description: Lipopolysaccharide (LPS) for endotoxin challenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide
Description: Lipopolysaccharide (LPS) for endotoxin challenge

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipopolysaccharide
Description: Lipopolysaccharide (LPS) for endotoxin challenge
Study: NCT01080365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-606 (Bosutinib)
Description: 500 mg commercial formulation film coated tablet, administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-606 (Bosutinib)
Description: 500 mg (5 ×100 mg) phase 3 formulation film coated tablets, administered orally once daily
Study: NCT03966638

Intervention type: PROCEDURE
Intervention: Intra-meniscal injection of platelet-rich plasma
Description: Intra-meniscal injection of platelet-rich plasma under echographic control
Study: NCT01162837

Intervention type: DEVICE
Group type: OTHER
Intervention: BEAM device
Description: A red/blue LED device for the treatment of acne
Study: NCT01469715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GBP CGM
Description: Visit 1: Screening visit to determine if subject qualifies for the study. Visit 2: Inpatient admission requiring a 25.5-hour hospital stay. Each subject will wear one active \& one mock device simultaneously during hyperglycemic \& hypoglycemic challenge conditions to observe a wide range of glucose values. Visit 3 \& 4: Subjects will return to the research center approximately 24 \& 48 hours after sensor removal, respectively, for evaluation of the postimplantation sensor site. Visit 5: Subjects will return to the research center approximately 28 days post inpatient admission. Blood samples for future testing of GBP and polyethylene Glycol neutralizing antibodies will be taken at Visit 1 \& 5.
Study: NCT03137199

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hMSCs
Description: intravenous infusion of bone marrow-derived allogeneic stem cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hMSCs
Description: intravenous infusion of bone marrow-derived allogeneic stem cells
Study: NCT04660916

Intervention type: DRUG
Intervention: Isotretinoin
Description: The effects of isotretinoin on morphology, growth rate, and thickness of the nail plate
Study: NCT01650597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279 2.5 - 500 mg oral
Description: Type=exact number, unit=mg, numbers=2.5, 10, 30, 100, 250 and 500, form=suspension, route=oral use. One single dose administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279 2.5 - 500 mg oral
Description: Type=exact number, unit=mg, numbers=2.5, 10, 30, 100, 250 and 500, form=suspension, route=oral use. One single dose administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279 100 mg oral
Description: Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.